Tag: relapsing-remitting

Moving away from traditional clinical categories of MS may lead to better, and more personalised treatments for MS.

FDA approves cladribine for people with relapsing forms of MS and active secondary progressive MS

Chronic Cerebrospinal Venous Insufficiency (CCSVI) describes a potential reduction in blood flow in the major veins that drain blood from the brain and spinal cord over a prolonged period.

Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US